{"id":"W4367395065","doi":"10.1038/s41416-023-02279-x","title":"A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Cancer Research UK; Incyte; NuCana; Astex Pharmaceuticals; Carrick Therapeutics; Sierra Oncology; National Institute for Health and Care Research; Verastem Oncology","keywords":"Medicine; Cancer; Oncology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001903493,0.0001131408,0.000285684,0.00008312691,0.00002223358,0.00001847375,0.0001700269,0.00008807057,0.00004620302],"category_scores_gemma":[0.00007289471,0.0001159945,0.00009860713,0.0002159753,0.00004458248,0.00001479776,0.00004718848,0.0001247414,6.80008e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000439839,"about_ca_system_score_gemma":0.0003707267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008557502,"about_ca_topic_score_gemma":0.0007302637,"domain_scores_codex":[0.9987645,0.000050618,0.0004653956,0.0001799095,0.0003227842,0.0002167704],"domain_scores_gemma":[0.99906,0.000007196408,0.0004115558,0.0001247232,0.0003077057,0.00008886526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1160806,0.002177395,0.01064712,0.0001396866,0.0004132274,0.0003713958,0.0001685431,0.0005978335,0.2822947,0.000005452072,0.00414493,0.5829591],"study_design_scores_gemma":[0.4460668,0.02743838,0.02999876,0.002329598,0.0001573286,0.00008860322,0.0001777109,0.0000334517,0.4640372,0.00007989021,0.0288338,0.0007584652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975099,0.001399943,0.00001732462,0.00005054157,0.0005634193,0.000280404,0.000116025,0.000005420274,0.00005704092],"genre_scores_gemma":[0.9977978,0.001281698,0.0002457224,0.00008086134,0.0002970221,0.00003973225,0.00002301201,0.00002902111,0.0002051045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5822006,"threshold_uncertainty_score":0.4730117,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009254080624268702,"score_gpt":0.2939590683124058,"score_spread":0.2847049876881371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}